RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

NEW YORK--(BUSINESS WIRE)--Apr 6, 2026--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc (“Ultragenyx” or the “Company”) (NASDAQ: RARE) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406247253/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta (“OI”), while also minimizing risk that patients in Ultragenyx’ Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate (“AFR”), such that the second interim analysis could be performed and presented to the investing public; and (ii) in truth, Ultragenyx’ optimism in the Phase III Orbit study’s results and interim analysis benchmark were misplaced because Ultragenyx failed to convey the risk associated with basing such threshold figures on Phase II results that had no placebo control group for appropriate comparison and thus had not ruled out that the reduction in AFR from that study could merely be triggered by an increased standard of care and the placebo effect of being provided a novel treatment.

On July 9, 2025, Ultragenyx revealed that the Phase III Orbit study failed to achieve statistical significance for the second interim analysis and that Phase III Orbit and Cosmic studies would now be “progressing toward final analysis.”

On this news, the price of Ultragenyx stock fell more than 25%, according to the complaint.

Then, on December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not “achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.” Ultragenyx allegedly attributed the study failure to a “low fracture rate in the placebo group” of Orbit and a trend that fell shy of statistical significance in Cosmic.

On this news, the price of Ultragenyx stock fell more than 42%, according to the complaint.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ultragenyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Ultragenyx Pharmaceutical class action, go to www.faruqilaw.com/RARE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

TORONTO (AP) — Dalton Rushing hit two solo home runs for his first career multihomer game and the Los Angeles Dodgers went deep five times to rout the Toronto Blue Jays 14-2 on Monday in a rematch of the 2025 World Series.

Teoscar Hernández and Freddie Freeman both hit two-run home runs and Shohei Ohtani added a solo blast.

After scoring 31 runs in a three game sweep at Washington, the Dodgers piled up 17 hits against the slumping Blue Jays. Rushing went 4 for 4 and also scored after he was hit by a pitch.

Rushing connected on Tommy Nance’s first pitch of the seventh, then went deep again off Spencer Miles in the eighth.

Hernández went 2 for 5 with a walk and drove in four while Freeman was 2 for 4 with a walk and three RBIs. Kyle Tucker had a hit, walked and scored three times, and drove in a run with a sacrifice fly. Andy Pages had two hits, including a two-run double.

Blue Jays catcher Tyler Heineman came on to pitch the ninth and retired the side in order, Toronto’s only 1-2-3 inning of the game.

The Blue Jays lost their fifth straight and saw right-hander and three-time Cy Young Award winner Max Scherzer (1-1) leave after two innings. The 41-year-old allowed two runs and two hits, walked one and struck out a pair.

Hernández homered off Scherzer in the first. Freeman drilled a 438-foot shot off Josh Fleming in the third.

Ohtani homered off Joe Mantiply in the sixth, his third in four games.

Making his first start of the season, Dodgers left-hander Justin Wrobleski (1-0) allowed one run and two hits in five innings.

2025 World Series MVP RHP Yoshinobu Yamamoto (1-1, 3.00) is scheduled to start Tuesday against Blue Jays RHP Kevin Gausman (0-0, 0.75).

__

AP MLB: https://apnews.com/hub/mlb

Toronto Blue Jays pitcher Max Scherzer works against the Los Angeles Dodgers during first-inning baseball game action in Toronto on Monday, April 6, 2026. (Frank Gunn/The Canadian Press via AP)

Los Angeles Dodgers pitcher Justin Wrobleski pumps his fist after a fly ball hit by Toronto Blue Jays' Vladimir Guerrero Jr. was caught during first-inning baseball game action in Toronto, Monday, April 6, 2026. (Frank Gunn/The Canadian Press via AP)

Los Angeles Dodgers' Shohei Ohtani (17) congratulates teammate Freddie Freeman (5) who comes in to score on his two-run home run against the Toronto Blue Jays during third-inning baseball game action in Toronto, Monday, April 6, 2026. (Frank Gunn/The Canadian Press via AP)

Los Angeles Dodgers' Teoscar Hernández celebrates after scoring on a two-run home run against the Toronto Blue Jays during first-inning baseball game action in Toronto, Monday, April 6, 2026. (Frank Gunn/The Canadian Press via AP)

Los Angeles Dodgers' Dalton Rushing (68) celebrates afte his second home run of the night with teammate Hyeseong Kim (6) during eighth-inning baseball game action against the Toronto Blue Jays in Toronto, Monday, April 6, 2026. (Frank Gunn/The Canadian Press via AP)